SG11201806982PA - Cinnolin-4-amine compounds and their use in treating cancer - Google Patents
Cinnolin-4-amine compounds and their use in treating cancerInfo
- Publication number
- SG11201806982PA SG11201806982PA SG11201806982PA SG11201806982PA SG11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- salts
- international
- astrazeneca
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/162605 Al 28 September 2017 (28.09.2017) WIPO I PCT 111111111111110111011111111111010111110111011111111011111111111111111111111111110111111 (51) International Patent Classification: CO7D 405/14 (2006.01) A61P 35/00 (2006.01) A61K 31/502 (2006.01) (21) International Application Number: PCT/EP2017/056592 (22) International Filing Date: 20 March 2017 (20.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/310,883 21 March 2016 (21.03.2016) US (71) Applicant: ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje (SE). (72) Inventors: PIKE, Kurt, Gordon; AstraZeneca, Hodgkin Building, Chesterford Research Park, Little Chesterford Essex CB10 1XL (GB). BARLAAM, Bernard, Chris- tophe; AstraZeneca Darwin Building, Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 OWG (GB). (74) Agent: JONES, Teyrnon; ASTRAZENECA INTELLEC- TUAL PROPERTY, Mereside, Alderley Park, Maccles- field Cheshire SK10 4TG (GB). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: — with international search report (Art. 21(3)) W O 20 17 / 16 2605 Al (54) Title: CINNOLIN-4-AMINE COMPOUNDS AND THEIR USE IN TREATING CANCER 0 R 2 R 3 (I) (57) : This specification generally relates to compounds of Formula (I). And pharmaceutically acceptable salts thereof, where R I , R 2 and R 3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts thereof; kits comprising such compounds and salts thereof; methods of manufacture of such compounds and salts thereof; intermediates useful in the manufacture of such compounds and salts thereof; and to methods of treating ATM kinase mediated dis - ease, including cancer, using compounds of Formula (I) and salts thereof alone or in combination with other therapies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310883P | 2016-03-21 | 2016-03-21 | |
| PCT/EP2017/056592 WO2017162605A1 (en) | 2016-03-21 | 2017-03-20 | Cinnolin-4-amine compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806982PA true SG11201806982PA (en) | 2018-09-27 |
Family
ID=58361025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806982PA SG11201806982PA (en) | 2016-03-21 | 2017-03-20 | Cinnolin-4-amine compounds and their use in treating cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190099421A1 (en) |
| EP (1) | EP3433251A1 (en) |
| JP (1) | JP2019512512A (en) |
| KR (1) | KR20180127419A (en) |
| CN (1) | CN108884084A (en) |
| AR (1) | AR107937A1 (en) |
| AU (1) | AU2017237394A1 (en) |
| BR (1) | BR112018068347A2 (en) |
| CA (1) | CA3017035A1 (en) |
| CO (1) | CO2018010951A2 (en) |
| DO (1) | DOP2018000197A (en) |
| IL (1) | IL261648A (en) |
| MA (1) | MA43733A (en) |
| MX (1) | MX2018011283A (en) |
| PE (1) | PE20181895A1 (en) |
| SG (1) | SG11201806982PA (en) |
| TW (1) | TW201808939A (en) |
| WO (1) | WO2017162605A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111344293A (en) * | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1, 3-dihydroimidazo [4, 5-c ] cinnolin-2-one compounds and their use in the treatment of cancer |
| CA3093499A1 (en) * | 2018-03-14 | 2019-09-19 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| KR20210061337A (en) * | 2018-09-14 | 2021-05-27 | 수저우 잔롱 파마 리미티드 | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5- as a selective modulator of telangiectasia mutant (ATM) kinase c]cinnolin-2-one and uses thereof |
| CN116194109A (en) | 2020-06-24 | 2023-05-30 | 阿斯利康(英国)有限公司 | Combination of antibody-drug conjugate and ATM inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SK285141B6 (en) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Use of quinazoline derivative, quinazoline derivative, process for preparation thereof and pharmaceutical composition containing thereof |
| EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CL2008000191A1 (en) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER. |
| WO2012101062A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| KR20140041583A (en) * | 2011-05-23 | 2014-04-04 | 엘란 파마슈티컬스, 엘엘씨 | Inhibitors of lrrk2 kinase activity |
| NO2714752T3 (en) * | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-20 JP JP2018549311A patent/JP2019512512A/en active Pending
- 2017-03-20 AU AU2017237394A patent/AU2017237394A1/en not_active Abandoned
- 2017-03-20 PE PE2018001829A patent/PE20181895A1/en not_active Application Discontinuation
- 2017-03-20 MA MA043733A patent/MA43733A/en unknown
- 2017-03-20 EP EP17712123.3A patent/EP3433251A1/en not_active Withdrawn
- 2017-03-20 US US16/086,742 patent/US20190099421A1/en not_active Abandoned
- 2017-03-20 CA CA3017035A patent/CA3017035A1/en not_active Abandoned
- 2017-03-20 MX MX2018011283A patent/MX2018011283A/en unknown
- 2017-03-20 KR KR1020187030086A patent/KR20180127419A/en unknown
- 2017-03-20 CN CN201780017874.XA patent/CN108884084A/en active Pending
- 2017-03-20 SG SG11201806982PA patent/SG11201806982PA/en unknown
- 2017-03-20 BR BR112018068347A patent/BR112018068347A2/en not_active IP Right Cessation
- 2017-03-20 WO PCT/EP2017/056592 patent/WO2017162605A1/en active Application Filing
- 2017-03-20 TW TW106109172A patent/TW201808939A/en unknown
- 2017-03-21 AR ARP170100697A patent/AR107937A1/en unknown
-
2018
- 2018-09-06 IL IL261648A patent/IL261648A/en unknown
- 2018-09-18 DO DO2018000197A patent/DOP2018000197A/en unknown
- 2018-10-12 CO CONC2018/0010951A patent/CO2018010951A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA43733A (en) | 2018-11-28 |
| DOP2018000197A (en) | 2018-10-15 |
| EP3433251A1 (en) | 2019-01-30 |
| TW201808939A (en) | 2018-03-16 |
| CA3017035A1 (en) | 2017-09-28 |
| PE20181895A1 (en) | 2018-12-11 |
| IL261648A (en) | 2018-10-31 |
| AR107937A1 (en) | 2018-06-28 |
| WO2017162605A1 (en) | 2017-09-28 |
| MX2018011283A (en) | 2019-05-27 |
| US20190099421A1 (en) | 2019-04-04 |
| AU2017237394A1 (en) | 2018-11-01 |
| KR20180127419A (en) | 2018-11-28 |
| JP2019512512A (en) | 2019-05-16 |
| CN108884084A (en) | 2018-11-23 |
| BR112018068347A2 (en) | 2019-01-15 |
| CO2018010951A2 (en) | 2018-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201806982PA (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906767XA (en) | Estrogen receptor modulators | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |